Tokuyama (4043) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
29 Jul, 2026Executive summary
Net sales increased year-over-year, driven by the consolidation of the TLS Group and growth in semiconductor-related product sales, despite a downturn in chemicals due to raw material shortages.
Operating profit declined year-over-year, mainly due to higher raw material and fuel costs and lower chemical sales.
Profit attributable to owners of parent rose slightly, supported by gains on sale of investment securities and improved extraordinary income.
Financial highlights
Q1 FY2026 net sales: ¥85,654 million (+4.7% YoY); operating profit: ¥6,076 million (-22.9% YoY); profit attributable to owners of parent: ¥5,204 million (+6.0% YoY).
Gross profit increased to ¥29,964 million from ¥27,975 million YoY.
Comprehensive income surged 54.1% to ¥7,571 million.
Basic EPS: ¥72.34 (up from ¥68.27 YoY).
Total assets as of June 30, 2026: ¥577,945 million; shareholders’ equity: ¥287,000 million; net assets: ¥301,952 million.
Outlook and guidance
FY2026 net sales forecast: ¥392,000 million (+12.2% YoY); operating profit forecast: ¥34,000 million (up 8.2% YoY); profit attributable to owners of parent: ¥26,000 million (+17.1% YoY).
Annual dividend forecast: ¥132/share (interim ¥60, year-end ¥72), marking four consecutive years of increases.
Assumptions: exchange rate 160 yen/USD, naphtha price 86,000 yen/kl for Q2–Q4.
Latest events from Tokuyama
- Operating profit surged 24% on higher sales, but profit attributable to owners declined 5.1%.4043
Q4 202628 Apr 2026 - Operating profit surged on strong semiconductor sales and acquisitions, despite lower revenue.4043
Q3 202630 Jan 2026 - Operating profit up 37.2% on cost improvements and semiconductor demand; major acquisition completed.4043
Q2 202629 Oct 2025 - Operating profit rose 5.1% despite lower sales, driven by cost improvements and semiconductor demand.4043
Q1 202629 Jul 2025 - Operating and net profit soared on cost cuts and semiconductor demand, with outlook steady.4043
Q2 202513 Jun 2025 - Operating profit and net income surged despite lower revenue, with guidance unchanged.4043
Q1 202513 Jun 2025 - Profits and sales are set to reach record highs, with a major healthcare acquisition ahead.4043
Q4 20256 Jun 2025 - Semiconductor and dental materials strength drove profit growth and revised guidance.4043
Q3 20255 Jun 2025